OCALA, Fla., June 08, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today reported positive progress in a mid-year update from the ongoing Phase 2 clinical ...

– Highlights clinical potential of RNA trans-splicing ribozyme platform technology SEOUL, South Korea, April 20, 2026 /PRNewswire/ -- Rznomics announced today that it presented interim clinical data ...

Passage Bio reports positive Phase 1/2 trial results for PBFT02 in frontotemporal dementia, with planned protocol amendments for safety optimization. Passage Bio, Inc. announced positive results from ...

SCOTTSDALE, Ariz., June 10, 2026 (GLOBE NEWSWIRE) -- Applied Biologics, a biopharmaceutical company advancing novel biologic therapies for chronic wounds, tissue repair, and degenerative disease, ...

GRI Bio, Inc. has received a recommendation from the Independent Data Monitoring Committee to continue its Phase 2a study of GRI-0621 for the treatment of idiopathic pulmonary fibrosis (IPF) following ...

We remain on track to report additional interim clinical study results (representing at least 6 or 12 months of follow-up for each study subject) on multiple patients in the first quarter of calendar ...

View source version on businesswire.com: https://www.businesswire.com/news/home/20260511135503/en/ The articles, information, and content displayed on this webpage ...

Study medication appears well tolerated, with favorable safety data across all blinded single ascending dose (SAD) cohorts ...

Interim trial results showed vaccine to be safe and induced immune responses against Lassa virus and rabies virus.

AIM ImmunoTech Inc. (NYSE American: AIM) ("AIM” or the "Company”) today reported positive progress in a mid-year update from the ongoing Phase 2 clinical study evaluating AIM’s drug Ampligen® ...